In terms of safety, research indicates that the incidence of fatal toxic reactions, such as myocarditis and pulmonary toxicity, associated with PD-1/PD-L1 inhibitors in lymphoma treatment is relatively low, with grade 3–4 AEs occurring in 1–14% of cases [49]. This evidence concerns the gene PDCD1 and lymphoma.